Innovative study design for paediatric clinical trials

European Journal of Clinical Pharmacology

Volumn 67, Issue SUPPL. 1, 2011, Pages

  Baiardi, Paola ^a   Giaquinto, Carlo ^b   Girotto, Silvia ^c   Manfredi, Cristina ^a   Ceci, Adriana ^a  

^a Department of Biostatistics   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^c Azienda ULSS 12   (Italy)

Author keywords

Clinical trial design; Clinical trials; Paediatrics; TEDDY

Indexed keywords

ADAPTIVE DESIGN; BAYES THEOREM; CHILD SAFETY; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; EXPERIMENTAL STUDY; GOLD STANDARD; HUMAN; METHODOLOGY; OUTCOMES RESEARCH; PEDIATRICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RANDOMIZED PLACEBO PHASE DESIGN; RANDOMIZED WITHDRAWAL DESIGN; RESEARCH ETHICS; REVIEW; SAMPLE SIZE; SEQUENTIAL DESIGN; STUDY DESIGN; SYSTEMATIC REVIEW; THREE STAGE CLINICAL TRIAL DESIGN; TREATMENT RESPONSE;

BAYES THEOREM; CHILD; HUMANS; PEDIATRICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; THERAPIES, INVESTIGATIONAL;

EID: 79955616718     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-011-0990-y     Document Type: Review

References (26)

1. European Parliament and the Council of the European Union (2001) Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Off J Eur Communities L121:34-44
2. European Parliament and the Council of the European Union (2006) Regulation (EC) No 1901/2006, 12 December 2006, on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. Off J Eur Union L378:1-19
3. European Parliament and the Council of the European Union (2006) Regulation (EC) No 1902/2006 of the European Parliament and of the Council of 20 December 2006 amending Regulation 1901/2006 on medicinal products for paediatric use. Off J Eur Union L378:20-21
4. European Medicines Agency (2001) ICH/Topic E11. Clinical Investigation of Medicinal Products in the Paediatric Population. Step 5 - Note for guidance on clinical investigation of medicinal products in the paediatric population. CPMP/ICH/2711/99. http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/WC500002926.pdf. Accessed 24 December 2010
5. Committee for Medicinal Products for Human Use - CHMP (2006) Guideline on clinical trials in small populations. Doc. Ref. CHMP/EWP/83561/2005. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003615.pdf. Accessed 24 December 2010
6. Committee for Medicinal Products for Human Use - CHMP (2009) Guideline on the clinical development of medicinal products for the treatment of cystic fibrosis. Doc. Ref. EMEA/CHMP/EWP/9147/2008. http://www.ema.europa.eu/docs/en- GB/document-library/Scientific-guideline/2009/12/WC500017055.pdf. Accessed 24 December 2010
7. Committee for Medicinal Products for Human Use - CHMP (2009) Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for use in the treatment of asthma in children and adolescents. Doc. Ref. CPMP/EWP/4151/00 Rev. 1. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003504.pdf. Accessed 24 December 2010
8. Committee for Medicinal Products for Human Use - CHMP (2010) Paediatric addendum to CHMP guideline on the clinical investigations of medicinal products for the treatment of pulmonary arterial hypertension. Draft. EMA/CHMP/EWP/213972/2010. http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2010/06/WC500091628.pdf. Accessed 24 December 2010
9. Committee for Medicinal Products for Human Use - CHMP (2010) Paediatric addendum to CHMP note for guidance on clinical investigation ofmedicinal products in the treatment of lipid disorders. Draft. EMA/CHMP/213057/2010. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/ 07/WC500094340.pdf. Accessed 24 December 2010
10. Committee for Proprietary Medicinal Products - CPMP (2003) Note for guidance on evaluation of anticancer medicinal products in man. Addendum on paediatric oncology. EMEA/CPMP/EWP/569/02. http://www.ema.europa.eu/docs/en-GB/ document-library/Scientific-guideline/2009/10/WC500003969.pdf. Accessed 24 December 2010
11. Committee for Medicinal Products for Human Use - CHMP (2008) Guideline on the clinical development of medicinal products for the treatment of HIV infection. Doc. Ref. EMEA/CPMP/EWP/633/02. http://www.ema.europa.eu/docs/en-GB/ document-library/Scientific-guideline/2009/09/WC500003460.pdf. Accessed 24 December 2010
12. Goodman SN (2005) Ethics and evidence in clinical trials. Clin Trials 2(3):195-196
13. Palmer CR, Rosenberger WF (1999) Ethics and practice: alternative designs for phase III randomized clinical trials. Control Clin Trials 20(2):172-186 (Pubitemid 29164458)
14. Della Pasqua O, Zimmerhackl L, Rose K (2007) Study and protocol design for paediatric patients of different ages. In: Rose K, van den Anker JN (eds) Guide to paediatric clinical research. Karger, Basel, pp 87-107
15. Goodman SN (2009) Stopping trials for efficacy: an almost unbiased view. Clin Trials 6(2):133-135
16. Van der Lee JH, Wesseling J, Tanck MW, Offringa M (2010) Sequential design with boundaries approach in pediatric intervention research reduces sample size. J Clin Epidemiol 63(1):19-27
17. Chow SC, Chang M (2008) Adaptive design methods in clinical trials - a review. Orphanet J Rare Dis 3:11
18. Schoenfeld DA, Zheng H, Finkelstein DM (2009) Bayesian design using adult data to augment pediatric trials. Clin Trials 6 (4):297-304
19. Goodman SN, Sladky JT (2005) A Bayesian approach to randomized controlled trials in children utilizing information from adults: the case of Guillain-Barré syndrome. Clin Trials 2(4):305-310 (Pubitemid 41306272)
20. Honkanen VE, Siegel AF et al (2001) A three-stage clinical trial design for rare disorders. Stat Med 20(20):3009-3021 (Pubitemid 32982525)
21. Chiron C, Dulac O, Pons G (2008) Antiepileptic drug development in children: considerations for a revisited strategy. Drugs 68 (1):17-25
22. Chiron C, Dulac O, Gram L (1996) Vigabatrin withdrawal randomized study in children. Epilepsy Res 25(3):209-215 (Pubitemid 26394542)
23. Chiron C, Tonnelier S, Rey E, Brunet ML, Tran A, d'Athis P, Vincent J, Dulac O, Pons G (2006) Stiripentol in childhood partial epilepsy: randomized placebo-controlled trial with enrichment and withdrawal design. J Child Neurol 21(6):496-502
24. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Pérez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalhães C, Sztajnbok F, Goldenstein-Schainberg C, Scheinberg M, Penades IC, Fischbach M, Orozco J, Hashkes PJ, Hom C, Jung L, Lepore L, Oliveira S, Wallace CA, Sigal LH, Block AJ, Covucci A, Martini A, Giannini EH, Paediatric Rheumatology International Trials Organization, Pediatric Rheumatology Collaborative Study Group (2008) Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 372(9636):383-391
25. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, Nemcova D, Mouy R, Sandborg C, Bohnsack J, Elewaut D, Foeldvari I, Gerloni V, Rovensky J, Minden K, Vehe RK, Weiner LW, Horneff G, Huppertz HI, Olson NY, Medich JR, Carcereri-De-Prati R, McIlraith MJ, Giannini EH, Martini A, Pediatric Rheumatology Collaborative Study Group, Pediatric Rheumatology International Trials Organisation (2008) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359(8):810-820
26. Feldman B, Wang E, Willan A, Szalai JP (2001) The randomized placebo-phase design for clinical trials. J Clin Epidemiol 54 (6):550-557 (Pubitemid 32453347)